JP2023538645A - ボロン酸化合物 - Google Patents

ボロン酸化合物 Download PDF

Info

Publication number
JP2023538645A
JP2023538645A JP2023512463A JP2023512463A JP2023538645A JP 2023538645 A JP2023538645 A JP 2023538645A JP 2023512463 A JP2023512463 A JP 2023512463A JP 2023512463 A JP2023512463 A JP 2023512463A JP 2023538645 A JP2023538645 A JP 2023538645A
Authority
JP
Japan
Prior art keywords
compound
mmol
mixture
added
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538645A5 (https=
Inventor
チン，ドンフイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaeno Therapeutics Co Ltd
Original Assignee
Phaeno Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phaeno Therapeutics Co Ltd filed Critical Phaeno Therapeutics Co Ltd
Publication of JP2023538645A publication Critical patent/JP2023538645A/ja
Publication of JP2023538645A5 publication Critical patent/JP2023538645A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023512463A 2020-08-20 2021-08-20 ボロン酸化合物 Pending JP2023538645A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010845001.1 2020-08-20
CN202010845001 2020-08-20
CN202110373982.9 2021-04-07
CN202110373982 2021-04-07
PCT/CN2021/113815 WO2022037680A1 (zh) 2020-08-20 2021-08-20 硼酸类化合物

Publications (2)

Publication Number Publication Date
JP2023538645A true JP2023538645A (ja) 2023-09-08
JP2023538645A5 JP2023538645A5 (https=) 2024-08-28

Family

ID=80322587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512463A Pending JP2023538645A (ja) 2020-08-20 2021-08-20 ボロン酸化合物

Country Status (7)

Country Link
US (1) US12590108B2 (https=)
EP (1) EP4201942A4 (https=)
JP (1) JP2023538645A (https=)
KR (1) KR20230104117A (https=)
CN (1) CN116615431A (https=)
TW (1) TW202214261A (https=)
WO (1) WO2022037680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
WO2025228222A1 (zh) * 2024-04-30 2025-11-06 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其应用
WO2026067428A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 硼酸衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033461A1 (en) * 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP2016502973A (ja) * 2012-12-07 2016-02-01 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2016149393A1 (en) * 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2019527196A (ja) * 2016-06-30 2019-09-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033461A1 (en) * 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP2016502973A (ja) * 2012-12-07 2016-02-01 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
WO2016149393A1 (en) * 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2019527196A (ja) * 2016-06-30 2019-09-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用

Also Published As

Publication number Publication date
WO2022037680A1 (zh) 2022-02-24
TW202214261A (zh) 2022-04-16
US12590108B2 (en) 2026-03-31
KR20230104117A (ko) 2023-07-07
CN116615431A (zh) 2023-08-18
US20240294554A1 (en) 2024-09-05
EP4201942A1 (en) 2023-06-28
EP4201942A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
KR20220086573A (ko) 융합된 피리돈 화합물, 및 이의 제조 방법 및 이의 용도
TW202304911A (zh) 吡啶醯胺類化合物
JP2023538645A (ja) ボロン酸化合物
CN104619713B (zh) 氧杂双环衍生物、制备方法及其应用
JP2016505619A (ja) ボロン酸誘導体及びその治療的使用
JP2022550427A (ja) Ｐｄ－１／ｐｄ－ｌ１小分子阻害剤としての化合物及びその使用
TW202128699A (zh) 治療性化合物
JP2023522863A (ja) Ｅｇｆｒ阻害剤としての三環式化合物
JP7299408B2 (ja) ＳＧＬＴｓ／ＤＰＰ４阻害剤およびその使用
KR102754529B1 (ko) Pd-l1 면역조절제인 플루오로 비닐 벤즈아미드 화합물
CN116234551A (zh) 一类1,7-萘啶类化合物及其应用
JP7663605B2 (ja) ピリミジン系三環式化合物及びその使用
TW202309013A (zh) 酮類衍生物
KR102500569B1 (ko) 선택적 btk 키나제 억제제로서의 피라졸로피리딘계 화합물
CN115427418A (zh) 一种肌醇衍生物及其用途
TWI814092B (zh) 稠合的三并環衍生物及其在藥學上的應用
JP7210771B2 (ja) Ｓｇｌｔ１阻害剤としてのグルコシド系誘導体およびその使用
JP2021501778A (ja) ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
HK40083691A (en) Inositol derivative and use thereof
HK40041288B (en) Fluorovinylbenzamide compound as pd-l1 immunomodulator
HK40041288A (en) Fluorovinylbenzamide compound as pd-l1 immunomodulator
HK40085541A (en) Class of 1,7-naphthyridine compounds and application thereof
WO2025119216A1 (zh) 硼酸类β-内酰胺酶抑制剂及其制备方法和应用
HK40068189A (en) Compound as small molecule inhibitor pd-1/pd-l1 and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105